ascopubs.org

The role of cisplatin (CDDP) or carboplatin (CARBO) plus pemetrexed (PEM) in nonsquamous (NON-SQM) non-small cell lung cancer (NSCLC): Results of an Italian retrospective ...

Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) ...
ascopubs.org

Phase I/II study of cisplatin (CDDP) and docetaxel (DOC) with concurrent chest radiotherapy followed by full dose of consolidation chemotherapy with CDDP/DOC in locally ...

Intrapatient dose escalation to 800 mg/m2 pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy No significant financial ...